Inflammasome Modulation by Chemotherapeutics in Malignant Mesothelioma

PLoS ONE

Volumn 10, Issue 12, 2015, Pages

  Westbom, Catherine ^a   Thompson, Joyce K ^a   Leggett, Alan ^a   MacPherson, Maximilian ^a   Beuschel, Stacie ^a   Pass, Harvey ^b   Vacek, Pamela ^a   Shukla, Arti ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CRYOPYRIN; CYTOCHALASIN D; DOXORUBICIN; FIBROBLAST GROWTH FACTOR 2; HIGH MOBILITY GROUP B1 PROTEIN; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; MONOCYTE CHEMOTACTIC PROTEIN 1; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; VASCULOTROPIN; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 18 PROTEIN, HUMAN; NLRP3 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MALE; MALIGNANT MESOTHELIOMA; MOUSE; NEUTROPHIL COUNT; NLRP3 GENE; NONHUMAN; PROTEIN EXPRESSION; PYROPTOSIS; REGULATORY MECHANISM; TREATMENT DURATION; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG SCREENING; GENETICS; LUNG NEOPLASMS; MESOTHELIOMA; METABOLISM; PATHOLOGY; PHYSIOLOGICAL FEEDBACK; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARRIER PROTEINS; CASPASE 1; CELL LINE, TUMOR; CISPLATIN; DOXORUBICIN; FEEDBACK, PHYSIOLOGICAL; HUMANS; INFLAMMASOMES; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-18; INTERLEUKIN-1BETA; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MICE, SCID; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; RECEPTORS, INTERLEUKIN-1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84956904264     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0145404     Document Type: Article

References (42)

1. Smythe WR. Current therapy for malignant mesothelioma. Current oncology reports. 2002; 4(4):305-13. Epub 2002/06/05. PMID: 12044240.
2. Hillegass JM, Shukla A, Lathrop SA, MacPherson MB, Beuschel SL, Butnor KJ, et al. Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model. Annals of the New York Academy of Sciences. 2010; 1203:7-14. Epub 2010/08/19. doi: 10.1111/j.1749-6632. 2010.05554.x PMID: 20716277; PubMed Central PMCID: PMC2936775.
3. Westbom CM, Shukla A, MacPherson MB, Yasewicz EC, Miller JM, Beuschel SL, et al. CREB-induced inflammation is important for malignant mesothelioma growth. The American journal of pathology. 2014; 184(10):2816-27. Epub 2014/08/12. doi: 10.1016/j.ajpath.2014.06.008 PMID: 25111229; PubMed Central PMCID: PMC4188864.
4. Petrilli V, Dostert C, Muruve DA, Tschopp J. The inflammasome: A danger sensing complex triggering innate immunity. Current opinion in immunology. 2007; 19(6):615-22. Epub 2007/11/06. doi: 10.1016/j. coi.2007.09.002 PMID: 17977705.
5. Krelin Y, Voronov E, Dotan S, Elkabets M, Reich E, Fogel M, et al. Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer research. 2007; 67(3):1062-71. Epub 2007/02/07. doi: 10.1158/0008-5472.CAN-06-2956 PMID: 17283139.
6. Idris A, Ghazali NB, Koh D. Interleukin 1beta-A Potential Salivary Biomarker for Cancer Progression? Biomarkers in cancer. 2015; 7:25-9. Epub 2015/08/06. doi: 10.4137/BIC.S25375 PMID: 26244033; PubMed Central PMCID: PMC4498652.
7. Wang Y, Faux SP, Hallden G, Kirn DH, Houghton CE, Lemoine NR, et al. Interleukin-1beta and tumour necrosis factor-alpha promote the transformation of human immortalised mesothelial cells by erionite. International journal of oncology. 2004; 25(1):173-8. Epub 2004/06/18. PMID: 15202003.
8. Hillegass JM, Miller JM, MacPherson MB, Westbom CM, Sayan M, Thompson JK, et al. Asbestos and erionite prime and activate the NLRP3 inflammasome that stimulates autocrine cytokine release in human mesothelial cells. Particle and fibre toxicology. 2013; 10:39. Epub 2013/08/14. doi: 10.1186/1743-8977-10-39 PMID: 23937860; PubMed Central PMCID: PMC3751315.
9. Siegmund B, Lehr HA, Fantuzzi G, Dinarello CA. IL-1 beta-converting enzyme (caspase-1) in intestinal inflammation. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98(23):13249-54. Epub 2001/10/19. doi: 10.1073/pnas.231473998 PMID: 11606779; PubMed Central PMCID: PMC60856.
10. Bauer C, Duewell P, Mayer C, Lehr HA, Fitzgerald KA, Dauer M, et al. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut. 2010; 59(9):1192-9. Epub 2010/05/06. doi: 10.1136/gut.2009.197822 PMID: 20442201.
11. Allen IC, TeKippe EM, Woodford RM, Uronis JM, Holl EK, Rogers AB, et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. The Journal of experimental medicine. 2010; 207(5):1045-56. Epub 2010/04/14. doi: 10.1084/jem.20100050 PMID: 20385749; PubMed Central PMCID: PMC2867287.
12. Zaki MH, Vogel P, Malireddi RK, Body-Malapel M, Anand PK, Bertin J, et al. The NOD-like receptor NLRP12 attenuates colon inflammation and tumorigenesis. Cancer cell. 2011; 20(5):649-60. Epub 2011/11/19. doi: 10.1016/j.ccr.2011.10.022 PMID: 22094258; PubMed Central PMCID: PMC3761879.
13. Dickson MA, Hahn WC, Ino Y, Ronfard V, Wu JY, Weinberg RA, et al. Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Molecular and cellular biology. 2000; 20(4):1436-47. PMID: 10648628.
14. Pass HI, Stevens EJ, Oie H, Tsokos MG, Abati AD, Fetsch PA, et al. Characteristics of nine newly derived mesothelioma cell lines. The Annals of thoracic surgery. 1995; 59(4):835-44. Epub 1995/04/01 PMID: 7695406.
15. Reale FR, Griffin TW, Compton JM, Graham S, Townes PL, Bogden A. Characterization of a human malignant mesothelioma cell line (H-MESO-1): A biphasic solid and ascitic tumor model. Cancer research. 1987; 47(12):3199-205. PMID: 3555770.
16. Shukla A, Hillegass JM, MacPherson MB, Beuschel SL, Vacek PM, Pass HI, et al. Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin. Molecular cancer. 2010; 9:314. Epub 2010/12/17. doi: 10.1186/1476-4598-9-314 PMID: 21159167; PubMed Central PMCID: PMC3016286.
17. Shukla A, Miller JM, Cason C, Sayan M, MacPherson MB, Beuschel SL, et al. Extracellular signal-regulated kinase 5: A potential therapeutic target for malignant mesotheliomas. Clinical cancer research: An official journal of the American Association for Cancer Research. 2013; 19(8):2071-83. Epub 2013/03/07 doi: 10.1158/1078-0432.CCR-12-3202 PMID: 23446998; PubMed Central PMCID: PMC3630261.
18. Newick K, Cunniff B, Preston K, Held P, Arbiser J, Pass H, et al. Peroxiredoxin 3 is a redox-dependent target of thiostrepton in malignant mesothelioma cells. PloS one. 2012; 7(6):e39404. Epub 2012/07/05. doi: 10.1371/journal.pone.0039404 PMID: 22761781; PubMed Central PMCID: PMC3382597.
19. Hillegass JM, Blumen SR, Cheng K, MacPherson MB, Alexeeva V, Lathrop SA, et al. Increased efficacy of doxorubicin delivered in multifunctional microparticles for mesothelioma therapy. International journal of cancer Journal international du cancer. 2011; 129(1):233-44. Epub 2010/09/11. doi: 10. 1002/ijc.25666 PMID: 20830711; PubMed Central PMCID: PMC3017728.
20. Park MS, De Leon M, Devarajan P. Cisplatin induces apoptosis in LLC-PK1 cells via activation of mitochondrial pathways. Journal of the American Society of Nephrology: JASN. 2002; 13(4):858-65. Epub 2002/03/26. PMID: 11912244.
21. Shukla A, Barrett TF, Nakayama KI, Nakayama K, Mossman BT, Lounsbury KM. Transcriptional upregulation of MMP12 and MMP13 by asbestos occurs via a PKCdelta-dependent pathway in murine lung. Faseb J. 2006; 20(7):997-9. PMID: 16571779.
22. Shukla A, Barrett TF, Nakayama KI, Nakayama K, Mossman BT, Lounsbury KM. Transcriptional upregulation of MMP12 and MMP13 by asbestos occurs via a PKCdelta-dependent pathway in murine lung. FASEB journal: Official publication of the Federation of American Societies for Experimental Biology. 2006; 20(7):997-9. Epub 2006/03/31. doi: 10.1096/fj.05-4554fje PMID: 16571779.
23. Shukla A, Hillegass JM, MacPherson MB, Beuschel SL, Vacek PM, Butnor KJ, et al. ERK2 is essential for the growth of human epithelioid malignant mesotheliomas. International journal of cancer Journal international du cancer. 2011; 129(5):1075-86. Epub 2011/06/29. doi: 10.1002/ijc.25763 PMID: 21710492; PubMed Central PMCID: PMC3071888.
24. Shukla A, Bosenberg MW, MacPherson MB, Butnor KJ, Heintz NH, Pass HI, et al. Activated cAMP response element binding protein is overexpressed in human mesotheliomas and inhibits apoptosis. The American journal of pathology. 2009; 175(5):2197-206. Epub 2009/10/10. doi: 10.2353/ajpath. 2009.090400 PMID: 19815709; PubMed Central PMCID: PMC2774081.
25. Schwarznau A, Hanson MS, Sperger JM, Schram BR, Danobeitia JS, Greenwood KK, et al. IL-1beta receptor blockade protects islets against pro-inflammatory cytokine induced necrosis and apoptosis. Journal of cellular physiology. 2009; 220(2):341-7. Epub 2009/04/01. doi: 10.1002/jcp.21770 PMID: 19334038; PubMed Central PMCID: PMC2890273.
26. Dinarello CA, Simon A, Van Der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nature reviews Drug discovery. 2012; 11(8):633-52. Epub 2012/08/02. doi: 10. 1038/nrd3800 PMID: 22850787.
27. Hillegass JM, Shukla A, Lathrop SA, MacPherson MB, Fukagawa NK, Mossman BT. Assessing nanotoxicity in cells in vitro. Wiley interdisciplinary reviews Nanomedicine and nanobiotechnology. 2010; 2 (3):219-31. Epub 2010/01/12. doi: 10.1002/wnan.54 PMID: 20063369; PubMed Central PMCID: PMC2854858.
28. Antonopoulos C, Russo HM, El Sanadi C, Martin BN, Li X, Kaiser WJ, et al. Caspase-8 as an Effector and Regulator of NLRP3 Inflammasome Signaling. The Journal of biological chemistry. 2015; 290 (33):20167-84. Epub 2015/06/24. doi: 10.1074/jbc.M115.652321 PMID: 26100631; PubMed Central PMCID: PMC4536427.
29. Palomo J, Dietrich D, Martin P, Palmer G, Gabay C. The interleukin (IL)-1 cytokine family-Balance between agonists and antagonists in inflammatory diseases. Cytokine. 2015. Epub 2015/07/18. doi: 10.1016/j.cyto.2015.06.017 PMID: 26185894.
30. Lamkanfi M, Kanneganti TD, Van Damme P, Vanden Berghe T, Vanoverberghe I, Vandekerckhove J, et al. Targeted peptidecentric proteomics reveals caspase-7 as a substrate of the caspase-1 inflammasomes. Molecular & cellular proteomics: MCP. 2008; 7(12):2350-63. Epub 2008/08/01. doi: 10.1074/mcp.M800132-MCP200 PMID: 18667412; PubMed Central PMCID: PMC2596343.
31. Winter RN, Kramer A, Borkowski A, Kyprianou N. Loss of caspase-1 and caspase-3 protein expression in human prostate cancer. Cancer research. 2001; 61(3):1227-32. Epub 2001/02/28. PMID: 11221855.
32. Winter RN, Rhee JG, Kyprianou N. Caspase-1 enhances the apoptotic response of prostate cancer cells to ionizing radiation. Anticancer research. 2004; 24(3a):1377-86. Epub 2004/07/28. PMID: 15274298.
33. Creagh EM. Caspase crosstalk: Integration of apoptotic and innate immune signalling pathways. Trends in immunology. 2014; 35(12):631-40. Epub 2014/12/03. doi: 10.1016/j.it.2014.10.004 PMID: 25457353.
34. Antonopoulos C, El Sanadi C, Kaiser WJ, Mocarski ES, Dubyak GR. Proapoptotic chemotherapeutic drugs induce noncanonical processing and release of IL-1beta via caspase-8 in dendritic cells. J Immunol. 2013; 191(9):4789-803. Epub 2013/10/01. doi: 10.4049/jimmunol.1300645 PMID: 24078693; PubMed Central PMCID: PMC3870469.
35. Bruchard M, Mignot G, Derangere V, Chalmin F, Chevriaux A, Vegran F, et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nature medicine. 2013; 19(1):57-64. Epub 2012/12/04. doi: 10.1038/nm.2999 PMID: 23202296.
36. Lee DW, Faubel S, Edelstein CL. A pan caspase inhibitor decreases caspase-1, IL-1alpha and IL-1beta, and protects against necrosis of cisplatin-treated freshly isolated proximal tubules. Renal failure. 2014:1-7. Epub 2014/10/14. doi: 10.3109/0886022X.2014.970194 PMID: 25310769.
37. Zhang Y, Yuan F, Cao X, Zhai Z, Gang Huang, Du X, et al. P2X7 receptor blockade protects against cisplatin-induced nephrotoxicity in mice by decreasing the activities of inflammasome components, oxidative stress and caspase-3. Toxicology and applied pharmacology. 2014. Epub 2014/10/14. doi: 10. 1016/j.taap.2014.09.016 PMID: 25308879.
38. Wong J, Tran LT, Magun EA, Magun BE, Wood LJ. Production of IL-1beta by bone marrow-derived macrophages in response to chemotherapeutic drugs: Synergistic effects of doxorubicin and vincristine. Cancer biology & therapy. 2014; 15(10):1395-403. Epub 2014/07/22. doi: 10.4161/cbt.29922 PMID: 25046000; PubMed Central PMCID: PMC4130732.
39. Bruchard M, Ghiringhelli F. [Impact of chemotherapies on immunosuppression and discovery of new therapeutic targets]. Bulletin du cancer. 2014; 101(6):605-7. Epub 2014/06/06. doi: 10.1684/bdc.2014. 1936 PMID: 24899072.
40. Antonopoulos C, Dubyak GR. Chemotherapy engages multiple pathways leading to IL-1beta production by myeloid leukocytes. Oncoimmunology. 2014; 3(1):e27499. Epub 2014/05/07. doi: 10.4161/onci. 27499 PMID: 24800164; PubMed Central PMCID: PMC4006851.
41. Huang J, Ni J, Liu K, Yu Y, Xie M, Kang R, et al. HMGB1 promotes drug resistance in osteosarcoma. Cancer research. 2012; 72(1):230-8. Epub 2011/11/22. doi: 10.1158/0008-5472.CAN-11-2001 PMID: 22102692.
42. Pan B, Chen D, Huang J, Wang R, Feng B, Song H, et al. HMGB1-mediated autophagy promotes docetaxel resistance in human lung adenocarcinoma. Molecular cancer. 2014; 13:165. Epub 2014/07/06. doi: 10.1186/1476-4598-13-165 PMID: 24996221; PubMed Central PMCID: PMC4125709.